Photo credit: www.sciencedaily.com
Parkinson’s disease is a neurodegenerative condition typically diagnosed in advanced stages based on clinical symptoms, predominantly affecting motor functions. Unfortunately, by this stage, significant and irreversible damage has already occurred in the brain. The complexity of the disease, with its varying manifestations, often leads to diagnostic challenges and inaccuracies. However, researchers from the PRODI Center for Protein Diagnostics at Ruhr University Bochum in Germany, in collaboration with the biotech company betaSENSE, have identified a spinal fluid biomarker that promises to enable more accurate diagnoses at earlier stages of the disease. Their findings were published in the journal EMBO Molecular Medicine on April 25, 2025.
Understanding Parkinson’s Disease
This condition is marked by the degeneration of dopaminergic neurons in the brain, generally resulting in escalating motor difficulties as the disease progresses. While dopamine replacements can help mitigate these symptoms temporarily, the underlying issue remains unaddressed. A pivotal factor in the development of Parkinson’s disease is the misfolding of a key protein known as alpha-synuclein (αSyn). According to Professor Klaus Gerwert, founding and managing director at PRODI and CEO of betaSENSE, “The misfolding causes the protein to become sticky, leading to the formation of larger complexes called oligomers. These oligomers assemble into long fibrillar filaments, which eventually aggregate into substantial Lewy bodies within the brain.”
Innovative Diagnostic Technology
In two separate clinical studies involving 134 participants, researchers demonstrated that the detection of αSyn misfolding in bodily fluids delivered a sensitivity and specificity of over 90%, making it a promising biomarker for early diagnosis of Parkinson’s disease. The study utilized cerebrospinal fluid samples collected from patients at Parkinson’s centers in Bochum (St. Josef Hospital) and Kassel (Paracelsus-Elena-Klinik), and employed betaSENSE’s patented iRS (immuno-infrared sensor) technology for accurate measurement.
betaSENSE had previously successfully applied the iRS technology to Alzheimer’s diagnostics, showing that misfolded Aβ biomarkers could predict the risk of Alzheimer’s dementia as much as 17 years prior to clinical diagnosis. “Our approach has now been adapted for Parkinson’s, focusing on αSyn misfolding,” emphasizes Klaus Gerwert.
Implications for Parkinson’s Treatment Development
The implications of this diagnostic technology extend beyond early detection; it could significantly aid in the development of new therapeutics and provide evidence of their effectiveness in clinical trials.
Source
www.sciencedaily.com